Adam Weiner, Urologic Surgeon at Cedars-Sinai, shared a post on X:
“CAN-2409 + RT: not just delaying PSA failure, reducing residual tumor in the gland.
Phase 3, double-blind RCT.
745 pts w/ int/high-risk localized prostate cancer.
EBRT + intraprostatic CAN-2409/valacyclovir vs placebo.
CAN-2409 is a replication-defective adenoviral HSV-tk gene therapy injected into the prostate.
Valacyclovir acts as the prodrug to drive local tumor-cell kill + immune priming.
DFS improved: HR 0.70; median NR vs 86.1 mo.
Key nuance: DFS included local failure by centrally reviewed positive prostate biopsy, protocol biopsy ~2 yrs post-EBRT.
At 22-26 mo: positive biopsies 20% vs 36%; pCR 80% vs 63%.
No major toxicity penalty: grade ≥3 TEAEs 8% vs 7%; no treatment-related deaths. CAN-2409 may not just suppress biochemical recurrence, it may deepen local tumor eradication after RT.”
Title: Aglatimagene besadenovec (CAN-2409) with radiotherapy for patients with localised prostate cancer: a phase 3, multicentre, randomised, double-blind, placebo-controlled trial
Authors: Theodore L. DeWeese, Andrea Manzanera, John Sylvester, Thomas Wheeler, Thomas Schroeder, Glen Gejerman, Gregory Chesnut, Thomas M. Facelle, Mark G. Garzotto, Christopher Pieczonka, Nilay M. Gandhi, Steven Sukin, Michael A. Liss, Ronald Tutrone, Bryan Mehlhaff, Stephen J. Savage, Megan Goody, Jenessa Vogt, Shangbang Rao, Maria Lucia Silva Polanco, Francesca Barone, W. Garrett Nichols, Paul P. Tak
Read the full article on The Lancet Oncology.
Other articles about Prostate Cancer on OncoDaily.
